The impact of thrombocytopenia on infection in patients with ST-elevation myocardial infarction (STEMI) remains poorly understood. To evaluate the association between thrombocytopenia and infection in patients with STEMI. Patients diagnosed with STEMI were identified from January 2010 to June 2016. The primary endpoint was in-hospital infection, and major adverse clinical events (MACE) and all-cause death were considered as secondary endpoints. A total of 1401 STEMI patients were enrolled and divided into two groups according to the presence (n = 186) or absence (n = 1215) of thrombocytopenia. The prevalence of in-hospital infection was significantly higher in the thrombocytopenic group (30.6% (57/186) vs. 16.2% (197/1215), p < 0.001). Prevalence of in-hospital MACE (30.1% (56/186) vs. 16.4% (199/1215), p < 0.001) and all-cause death (8.1% (15/186) vs. 3.8% (46/1215), p = 0.008) revealed an increasing trend. Multivariate analysis indicated that thrombocytopenia was independently associated with increased in-hospital infection (OR, 2.09; 95%CI 1.32–3.27; p = 0.001) and MACE (1.92; 1.27–2.87; p = 0.002), but not all-cause death (1.87; 0.88–3.78; p = 0.091). After a median follow-up of 2.85 years, thrombocytopenia was not associated with all-cause death at multivariable analysis (adjusted hazard ratio, 1.19; 95%CI 0.80–1.77; p = 0.383). Thrombocytopenia is significantly correlated with in-hospital infection and MACE, and might be used as a prognostic tool in patients with STEMI.

中文翻译：

---

ST段抬高型心肌梗死经皮冠状动脉介入治疗患者血小板减少与感染的关系

血小板减少对 ST 段抬高型心肌梗死 (STEMI) 患者感染的影响仍知之甚少。评估 STEMI 患者血小板减少症与感染之间的关联。从 2010 年 1 月至 2016 年 6 月确定诊断为 STEMI 的患者。主要终点是院内感染，主要不良临床事件（MACE）和全因死亡被视为次要终点。共招募了 1401 名 STEMI 患者，并根据血小板减少症的存在（n = 186）或不存在（n = 1215）分为两组。血小板减少组的院内感染发生率显着更高（30.6% (57/186) 与 16.2% (197/1215)，p < 0.001）。院内 MACE 的患病率 (30.1% (56/186) 与 16.4% (199/1215)，p < 0.001) 和全因死亡 (8. 1% (15/186) 与 3.8% (46/1215)，p = 0.008) 显示出增加的趋势。多变量分析表明，血小板减少症与院内感染增加（OR，2.09；95%CI 1.32–3.27；p = 0.001）和 MACE（1.92；1.27–2.87；p = 0.002）独立相关，但与全因死亡无关（1.87；0.88–3.78；p = 0.091）。中位随访 2.85 年后，多变量分析显示血小板减少症与全因死亡无关（调整后的风险比，1.19；95%CI 0.80–1.77；p = 0.383）。血小板减少症与院内感染和 MACE 显着相关，可用作 STEMI 患者的预后工具。32–3.27；p = 0.001）和 MACE（1.92；1.27–2.87；p = 0.002），但不是全因死亡（1.87；0.88–3.78；p = 0.091）。中位随访 2.85 年后，多变量分析显示血小板减少症与全因死亡无关（调整后的风险比，1.19；95%CI 0.80–1.77；p = 0.383）。血小板减少症与院内感染和 MACE 显着相关，可用作 STEMI 患者的预后工具。32–3.27；p = 0.001）和 MACE（1.92；1.27–2.87；p = 0.002），但不是全因死亡（1.87；0.88–3.78；p = 0.091）。中位随访 2.85 年后，多变量分析显示血小板减少症与全因死亡无关（调整后的风险比，1.19；95%CI 0.80–1.77；p = 0.383）。血小板减少症与院内感染和 MACE 显着相关，可用作 STEMI 患者的预后工具。